Video - Results from #20

Hot Topic QuickTakes VL

Search

Axumin™ (Fluciclovine F 18) Injection for PET Imaging of Recurrent Prostate Cancer - Phillip Koo Details In this 5 for 5 Hot Topics, Phillip Koo, MD. presents the clinical background of Axumin™ (Fluciclovine F 18) Injection for PET Imaging of Recurrent Prostate Cancer, the first FDA-approved F18 PET Imaging Agent indicated in for use in patients with suspected recurrent prostate cancer. Dr. Koo discusses its use for men with suspected prostate cancer recurrence based on elevated PSA levels following...
Effect of DRE on the 4Kscore for Aggressive prostate cancer with Michael Maccini. Details Michael Maccini, MD. presenting the "Effect of DRE on the 4Kscore for Aggressive Prostate Cancer" for E. David Crawford's 5 for 5. The 4Kscore is a new test using total PSA, free PSA, intact PSA, and human kallikrein 2 (hk2) combined with age, digital rectal exam (DRE) findings, and prior biopsy status to more accurately predict risk of Gleason score ≥7 on prostate biopsy. Prior studies examining...
$Radiotherapy for Prostate Cancer: Hypofractionation of Radiation - Jason Efstathiou$ Radiotherapy for Prostate Cancer: Hypofractionation of Radiation - Jason Efstathiou Details In this edition of 5 for 5, Dr. Jason Efstathiou discusses the benefits of hypofractionation and the radiobiological potential for therapeutic gain in prostate cancer. Dr. Efstathiou reviews the NRG Oncology RTOG 0415, RTOG 0938 studies and the CHHiP Trial. Results from these trials and other moderate hypofractionation trials lead to conclusions that hypofractionation is safe and effective and has...
Radiotherapy for Prostate Cancer 2016: Postoperative Radiation Therapy - Jason Efstathiou Details In this edition of 5 for 5, E. David Crawford invites Jason Efsathiou to discuss postoperative radiation in men that are at risk of failing radical prostatectomy. Biography: Jason A. Efstathiou, MD, DPhil Associate Professor Director, Genitourinary Division Department of Radiation Oncology Clinical Co-Director, Bertucci Center for GU Cancers Massachusetts General Hospital Harvard Medical School
What is the Significance of GS6? E. David Crawford interviews Scott Lucia Details M. Scott Lucia, MD. Vice Chair of the Department of Pathology; Director of Anatomic Pathology ; Director of the Prostate Diagnostic Laboratory presents an update on the Gleason scoring system and the recent modifications of the tumors. Dr. Lucia discusses current thinking on the risk of progression versus overtreatment in prostate cancer.
Nelson Stone Presents Transrectal or Transperineal Mapping Biopsy Details Transrectal or Transperineal Mapping Biopsy "Is it time for the new “gold standard?”